Anthony Wignall

Aug 2, 2024 | biorxiv.org | Kate Collins |Srinivas Kamath |Tahlia R. Meola |Anthony Wignall

AbstractAtypical antipsychotics are crucial for the management of schizophrenia and bipolar disorder, yet they exhibit significant pharmacokinetic variability which leads to inconsistent therapeutic responses. This study investigates the hypothesis that gut microbiome composition critically influences the oral bioavailability of lurasidone, a poorly soluble weak base antipsychotic with pH-dependent solubility.

Aug 2, 2024 | biorxiv.org | Kate Collins |Srinivas Kamath |Tahlia R. Meola |Anthony Wignall

AbstractAtypical antipsychotics are crucial for the management of schizophrenia and bipolar disorder, yet they exhibit significant pharmacokinetic variability which leads to inconsistent therapeutic responses. This study investigates the hypothesis that gut microbiome composition critically influences the oral bioavailability of lurasidone, a poorly soluble weak base antipsychotic with pH-dependent solubility.

Jul 19, 2024 | biorxiv.org | Kate Collins |Srinivas Kamath |Tahlia R. Meola |Anthony Wignall

AbstractThis study investigates the impact of gut microbiome composition on the bioavailability and biodistribution of lurasidone hydrochloride, an atypical antipsychotic used in treating mental health conditions. The research aims to uncover the relationship between gut metabolome, specifically short-chain fatty acids (SCFAs), and lurasidone absorption through modulation of intestinal pH.

Mar 3, 2024 | biorxiv.org | Srinivas Kamath |Alexander Hunter |Kate Collins |Anthony Wignall

AbstractAntipsychotics like olanzapine are associated with significant metabolic dysfunction, attributable to gut microbiota dysbiosis. A recent notion that most psychotropics are detrimental to the gut microbiota has arisen from consistent findings of metabolic adverse effects. However, unlike olanzapine, the metabolic effects of lurasidone are conflicting, with most reports observing weight loss rather than gain.